Amarin Corporation plc - ADR logo

Amarin Corporation plc - ADR (EH3A)

Delisted
XDUS XDUS
Want to track EH3A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EH3A is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Zacks | 2 days ago
Are Medical Stocks Lagging Amarin (AMRN) This Year?

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks | 2 weeks ago
Best Momentum Stock to Buy for June 27th

Best Momentum Stock to Buy for June 27th

GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.

Zacks | 2 weeks ago

Amarin Corporation plc - ADR Profile

Biotechnology Industry
Healthcare Sector
Aaron D. Berg CEO
XDUS Exchange
US0231114044 ISIN
IE Country
275 Employees
- Last Dividend
11 Apr 2025 Last Split
- IPO Date

Overview

Amarin Corporation plc stands as a noteworthy entity within the pharmaceutical landscape, dedicating its efforts to developing and commercializing therapeutic treatments aimed at combating cardiovascular diseases. With a geographical footprint spanning the United States, various European countries, Canada, Lebanon, and the United Arab Emirates, Amarin has established a significant presence in the global healthcare sector. The company's journey began under the name Ethical Holdings plc but underwent a rebranding to Amarin Corporation plc in 1999, marking a new chapter in its history. Since its inception in 1989, Amarin has been headquartered in Dublin, Ireland, serving as a testament to its enduring commitment to advancing cardiovascular health through innovative pharmaceutical solutions. At the heart of its collaborative endeavors is a strategic partnership with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of drug products and new therapeutic indications derived from the active pharmaceutical ingredient in its flagship product, Vascepa.

Products and Services

  • VASCEPA

VASCEPA stands out as Amarin Corporation plc's premier product offering, distinguished by its formulation as a prescription-only omega-3 fatty acid. This distinctive pharmacological product is specifically designed as an adjunct to diet for the purpose of reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. The commercialization of VASCEPA primarily targets wholesalers and specialty pharmacy providers, thereby ensuring its accessibility to the patient population in need of this critical intervention for managing cardiovascular health. Through this endeavor, Amarin accentuates its commitment to addressing the intricate challenges associated with cardiovascular diseases, leveraging the therapeutic potential of omega-3 fatty acids to enhance patient outcomes.

Contact Information

Address: Grand Canal Docklands
Phone: 353 1 669 9020